I’m working on several projects with the common theme of drug design. I’m developing high-affinity miniprotein inhibitors for IL-23R and IL-17A and F for therapy for autoimmune diseases. Super-stable designed proteins can provide a safer, cheaper, more convenient alternative to the standard of care, i.e. infused or injected antibodies. I’m also learning more about cyclic peptide design through two projects targeting cancer: designing PROTACs that bind KRAS and an E3 ligase, and cell-permeable inhibitors of N-Myc’s interaction with Aurora Kinase A.
Sioux Falls, South Dakota